Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 44

Results For "IQVIA"

501 News Found

Alembic receives USFDA tentative approval for fesoterodine fumarate
Drug Approval | February 02, 2022

Alembic receives USFDA tentative approval for fesoterodine fumarate

The tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency


Alembic receives USFDA approval for clarithromycin tablets
Drug Approval | February 01, 2022

Alembic receives USFDA approval for clarithromycin tablets

Clarithromycin tablets USP, 250 mg and 500 mg have an estimated market size of US $ 11 million for twelve months ending September 2021 according to IQVIA


Granules receives ANDA approval for potassium chloride for oral solution USP, 20 mEq
Drug Approval | January 28, 2022

Granules receives ANDA approval for potassium chloride for oral solution USP, 20 mEq

Potassium chloride is used to prevent or to treat low blood levels of potassium


Glenmark Pharmaceuticals receives ANDA approval for metronidazole vaginal gel, 0.75%
Drug Approval | January 28, 2022

Glenmark Pharmaceuticals receives ANDA approval for metronidazole vaginal gel, 0.75%

Glenmark’s current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA


Glenmark receives ANDA approval for hydrochlorothiazide tablets
Drug Approval | January 27, 2022

Glenmark receives ANDA approval for hydrochlorothiazide tablets

According to IQVIA sales data for the 12-month period ending November 2021, the Ziac tablets, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg market achieved annual sales of approximately US $ 30.3 million


Cipla’s Q3FY22 PAT at Rs 729 cr.
News | January 26, 2022

Cipla’s Q3FY22 PAT at Rs 729 cr.

Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.


JBCPL to acquire brands from Sanzyme for Rs 628 cr
News | January 26, 2022

JBCPL to acquire brands from Sanzyme for Rs 628 cr

Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise


Cosette Pharma acquires rights to Daiichi Sankyo’s eight branded products
Biotech | January 18, 2022

Cosette Pharma acquires rights to Daiichi Sankyo’s eight branded products

As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio


Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson injection
Drug Approval | January 17, 2022

Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson injection

The company has 47 ANDA's pending approval with the U.S.FDA


Strides receives USFDA approval for influenza medicine
Drug Approval | January 17, 2022

Strides receives USFDA approval for influenza medicine

The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval